Hematology/Oncology Clinics of North America This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary therapy increasingly used in the treatment of non-Hodgkin B-cell lymphoma. This review focuses on the use of CAR T-cell therapy in aggressive B-cell lymphoma including clinical indications, known short- and long-term toxicity, mechanisms of CAR T-cell efficacy and tumor resistance, and future directions in the treatment of aggressive lymphoma with CAR T-cell therapy. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 20, 2023 Category: Cancer & Oncology Authors: Mark P. Hamilton, David B. Miklos Source Type: research

Subspecialty Breast Imaging Education in Tanzania; Clinical, Infrastructure, and Logistical Paradigms for Best Practices in the Low- and Middle-Income Settings
We present subspecialty radiologist training for breast imaging at an Academic center in Dar Es Salaam, Tanzania. The training incorporates remote, in-person, asynchronous and synchronous teaching methods and multidisciplinary conferences. We use a team of US academic faculty under the auspices of the Radiological Society of North America Global Learning centers paradigm. Trainees are Tanzanian radiologists who are pursuing an additional specialization degree in Women ’s imaging, utilizing an approved 2-year curriculum. Challenges and opportunities in providing image-guided intervention and diagnosis training in the low-...
Source: Hematology/Oncology Clinics of North America - June 20, 2023 Category: Cancer & Oncology Authors: Toma S. Omofoye, Anganile Kalinga, Ramapriya Ganti, Frank J. Minja, Timothy B. Rooney Source Type: research

Surgical Management of Localized Disease and Small Renal Masses
This article provides a comprehensive review of the current surgical management options for localized renal cancer. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 15, 2023 Category: Cancer & Oncology Authors: Daniel S. Carson, Tova Weiss, Lisa Xinyuan Zhang, Sarah P. Psutka Source Type: research

Role of Surgery in Metastatic Renal Cell Carcinoma
Surgery has historically been the mainstay of treatment for metastatic renal cell carcinoma (mRCC), but recent clinical trials demonstrated that contemporary systemic therapies alone are non-inferior to cytoreductive nephrectomy (CN). Thus, the current role of surgery is not precisely defined. CN remains an appropriate upfront treatment for the palliation of severe symptoms, select cases of metastatic non-clear cell renal cell carcinoma, for consolidation following systemic therapy, and in the setting of oligometastatic disease. Metastasectomy is ideally utilized to achieve a disease-free state when there is minimal morbid...
Source: Hematology/Oncology Clinics of North America - June 15, 2023 Category: Cancer & Oncology Authors: Jos é Ignacio Nolazco, Steven Lee Chang Source Type: research

The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies
Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies are a class of T-cell engaging immunotherapies that have demonstrated considerable promise for patients with blood cancers. In comparison with traditional cancer therapeutics, T-cell engaging therapies harness the power of the host immune system to attack malignant cells expressing a target antigen of interest. Although these therapies are altering the natural history of blood cancers, the availability of several products has created uncertainty regarding treatment selection. In this review, we discuss the role of CAR T-cell therapy in the emerging er...
Source: Hematology/Oncology Clinics of North America - June 15, 2023 Category: Cancer & Oncology Authors: Karthik Nath, Sham Mailankody, Saad Z. Usmani Source Type: research

An Overview of Cervical Cancer Prevention and Control in Latin America and the Caribbean Countries
Cervical cancer is a health crisis affecting women and their families across the world. It is known that developed countries have comprehensive protocols with recommendations regarding workforce, expertise, and medical resources to address this common cancer among women. In contrast, disparities in addressing cervical cancer remain present in Latin America and Caribbean countries. Here, we reviewed the current strategies of cervical cancer prevention and control in the region. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 15, 2023 Category: Cancer & Oncology Authors: Ivy Riano, Pamela Contreras-Chavez, Cindy Medina Pabon, Kelly Meza, Lauren Kiel, Suyapa Bejarano, Narjust Florez Source Type: research

Breast Cancer in India
Breast cancer is the most common cancer in urban Indian women and the second most common cancer in all Indian women. The epidemiology as well as biology of this cancer seems to be different in the Indian subcontinent when compared with the West. The lack of population-based breast cancer screening programs and delay in seeking a medical consult due to financial and social reasons, including lack of awareness and fear related to a cancer diagnosis, results in delayed diagnosis. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 15, 2023 Category: Cancer & Oncology Authors: Prarthna V. Bhardwaj, Renuka Dulala, Senthil Rajappa, Chandravathi Loke Source Type: research

Renal Cell Cancer
Since the last renal cell carcinoma (RCC) issue of Hematology/Oncology Clinics of North America in 2011, the management of this disease has changed dramatically with more than 10 different approvals by the Food and Drug Administration for this indication across treatment settings. New options now exist for some hereditary syndromes; adjuvant therapy, and most importantly, combination therapies are now the standard for front line, with new options available for patients with metastatic disease. At the time of this writing, several other new therapies are on the horizon. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 15, 2023 Category: Cancer & Oncology Authors: Bradley A. McGregor, Toni K. Choueiri Tags: Preface Source Type: research

Providing Diagnostic Pathology Services in Low and Middle-Income Countries
Diagnostic pathology services in low and middle-income countries are often hindered by lack of expertise, equipment, and reagents. However, there are also educational, cultural, and political decisions, which must be addressed in order to provide these services successfully. In this review, we describe some of the infrastructure barriers that must be overcome and provide 3 examples of implementing molecular testing in Rwanda and Honduras despite initial lack of resources. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 14, 2023 Category: Cancer & Oncology Authors: Deo Ruhangaza, Linda S. Kennedy, Gregory J. Tsongalis Source Type: research

Insights into Renal Cell Carcinoma with Novel Imaging Approaches
This article presents a comprehensive overview of new imaging approaches and techniques for improving the assessment of renal masses and renal cell carcinoma. The Bosniak classification, version 2019, as well as the clear cell likelihood score, version 2.0, will be discussed as new imaging algorithms using established techniques. Additionally, newer modalities, such as contrast-enhanced ultrasound, dual energy computed tomography, and molecular imaging, will be discussed in conjunction with emerging radiomics and artificial intelligence techniques. Current diagnostic algorithms combined with newer approaches may be an effe...
Source: Hematology/Oncology Clinics of North America - June 9, 2023 Category: Cancer & Oncology Authors: Khoschy Schawkat, Katherine M. Krajewski Source Type: research

von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology
The most common form of kidney cancer is clear cell renal cell carcinoma (ccRCC). Biallelic VHL tumor suppressor gene inactivation is the usual initiating event in both hereditary (VHL Disease) and sporadic ccRCCs. The VHL protein, pVHL, earmarks the alpha subunits of the HIF transcription factor for destruction in an oxygen-dependent manner. Deregulation of HIF2 drives ccRCC pathogenesis. Drugs inhibiting the HIF2-responsive growth factor VEGF are now mainstays of ccRCC treatment. A first-in-class allosteric HIF2 inhibitor was recently approved for treating VHL Disease-associated neoplasms and appears active against spora...
Source: Hematology/Oncology Clinics of North America - June 1, 2023 Category: Cancer & Oncology Authors: Nitin H. Shirole, William G. Kaelin Source Type: research

Prognostic Models in Metastatic Renal Cell Carcinoma
This article summarizes the available evidence on risk stratification and prognostic models for mRCC, including the International mRCC Database Consortium and Memorial Sloan Kettering Cancer Center models, as well as their association with clinical outcomes. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 1, 2023 Category: Cancer & Oncology Authors: Audreylie Lemelin, Kosuke Takemura, Daniel Y.C. Heng, Matthew S. Ernst Source Type: research

Management of Brain Metastases in Metastatic Renal Cell Carcinoma
The development of brain metastases is a poor prognostic indicator in renal cell carcinoma. Regular imaging and clinical examinations are necessary to monitor the brain before or during systemic therapy. Central nervous system-targeted radiation therapy, including stereotactic radiosurgery, whole-brain radiation therapy, and surgical resection, is a standard treatment option. Clinical trials are currently investigating the role of targeted therapy and immune checkpoint inhibitor combinations in treating brain metastases and decreasing intracranial disease progression. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - June 1, 2023 Category: Cancer & Oncology Authors: Elshad Hasanov, Eric Jonasch Source Type: research

Future Directions in the Frontline Management of Waldenstr öm Macroglobulinemia
Despite substantial progress in the clinical management of Waldenstr öm’s Macroglobulinemia (WM) and the emergence of chemotherapy-free approaches such as BTK inhibitors, WM is still a disease in which current treatments fail to cure and are in part associated with significant toxicities, compromising treatment outcome and quality of life. Thus, the vision for fut ure front-line therapy should be to develop regimens which combine improved efficacy and excellent applicability with a low toxicity profile. Conventional immunochemotherapy such as bendamustine-rituximab is highly active but limited by hematotoxicity and long...
Source: Hematology/Oncology Clinics of North America - June 1, 2023 Category: Cancer & Oncology Authors: Christian Buske, Maria Lia Palomba Source Type: research

Evaluation and Management of Bing –Neel Syndrome
Bing –Neel syndrome is a rare manifestation of Waldenström macroglobulinemia (WM), which is caused by infiltration of the malignant lymphoplasmacytic cells in the central nervous system. Patients can present with a diverse range of neurologic symptoms, and differentiation with other comorbidities seen in WM, such as immunoglobulin M-related polyneuropathy, can be challenging. Both the rarity of this disorder and the heterogeneity of the clinical presentation often cause a significant diagnostic delay with the risk of permanent neurologic damage. This review summarizes current knowledge regarding diagnosis, treatment and...
Source: Hematology/Oncology Clinics of North America - May 29, 2023 Category: Cancer & Oncology Authors: Sarah J. Schep, Josephine M.I. Vos, Monique C. Minnema Source Type: research